12:00 AM
 | 
Mar 04, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Status

ISIS-CRPRx: Phase II started

Isis began the double-blind, placebo-controlled, crossover, U.K. Phase II ASET trial to evaluate multiple doses of ISIS-CRPRx in about 20 patients with AF who have pacemakers. The product is...

Read the full 121 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >